APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
APOBEC mutagenesis is a common source of genetic heterogeneity in cancer, and APOBEC mutational signatures are enriched in metastatic and drug-resistant tumors. However, the mechanisms through which APOBEC3 enzymes promote tumor evolution remain unknown. In this study, we show that APOBEC3 activity contributes to the development of therapy-resistant cancer cells by promoting evolution of DTP cells. These findings offer insights into the role of APOBEC mutagenesis in cancer progression.
Authors
- Feinan Wu (ORCID: https://orcid.org/0000-0002-4962-1874)
- Jessica N. Becerra
- James V. Alvarez (ORCID: https://orcid.org/0000-0003-2910-7621)
- Nina Marie G. Garcia (ORCID: https://orcid.org/0000-0003-0039-4073)
- Ashley V. DiMarco (ORCID: https://orcid.org/0000-0001-7352-9093)
- Brock J. McKinney
- Matthew Fitzgibbon (ORCID: https://orcid.org/0009-0008-7557-0442)
- Sharan Srinivasan (ORCID: https://orcid.org/0009-0000-4129-4568)
Institutions
- Duke University (US)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0442
- Citations
- 8
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 7.49